Company intelligence / Profile preview
Siolta Therapeutics
San Carlos, California, United Statessioltatherapeutics.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 2
01
Overview
Siolta Therapeutics is advancing multiple programs, with its lead program STMC-103H in Phase 2 for preventing atopic diseases. The company has received a $2.9M NIH grant for manufacturing optimization and a Series C financing of $12 million.
- Therapeutic areas
- GastroenterologyWomen's HealthImmunologyRare Diseases
- Modalities
- Live Biotherapeutic Products (LBPs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Khosla VenturesCowellnex Co. Ltd (Kirin and Kyowa Kirin joint investment)Johns Hopkins University
Beyond the preview
Go deeper on Siolta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Siolta Therapeutics.